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AbstrACt
Objective In this systematic review on drug price 
comparison studies, we report on recent determinants 
of drug prices in a national and international context to 
facilitate regulation of drug prices by purchasers and 
policymakers worldwide. Determinants of drug prices 
were divided into non- modifiable and modifiable and 
were categorised as pertaining to a country’s income 
level, pharmaceutical market system and its policies and 
government.
Primary outcome Determinants of drug prices or price 
variance.
Design We systematically searched PubMed, EMBASE, 
Web of Science and Cochrane Library for peer- reviewed 
articles published between 2004 and 22 July 2020 that 
reported an association of the primary outcome with one 
or more determinants. We performed a best- evidence 
synthesis of these associations for determinants covered 
in at least three studies.
results 31 publications were included. Only one 
publication described net drug prices and 30 described 
retail drug prices. Five modifiable determinants were 
associated with lower retail prices: generic market portion, 
discounts, tendering policies, central (governmental) 
purchasing and pricing regulation schemes. The 
originators market portion and a system in which mark- 
ups are common were associated with higher retail prices. 
Retail prices were highest in the USA, even compared 
with other high- income countries. A positive association 
between national income level and drug retail prices could 
not be established among middle- income and high- income 
countries. Retail prices were highest in low- income 
countries when adjusted for purchasing power parity.
Conclusions Literature on determinants of net drug 
prices is extremely sparse. Various healthcare system 
interventions, market- specific and governmental 
regulations are consistently associated with lower retail 
prices. Some interventions are easily implementable 
in developing or middle- income countries, such as 
tendering, central purchasing and fixed pricing regulation 
schemes. Net drug price comparison studies are needed 
to overcome the lack of price transparency and to quantify 
the effectiveness of policy measures on net drug prices.
IntrODuCtIOn
The global average share of healthcare costs 
in gross domestic product (GDP) increased 
from 4.6% of GDP in 1970 to 9.0% of GDP 
in 2016.1 Several factors contributed to this 
rise, such as ageing populations, technolog-
ical advances, the development of (expen-
sive) new drugs and increased insurance 
coverage. Consequently, countries worldwide 
face the challenge of decreasing this health-
care cost burden. A significant driver of rising 
healthcare costs is pharmaceutical expendi-
ture, so interventions to decrease drug costs 
through lower drug prices are warranted. 
Pharmaceutical expenditure is expected to 
reach 1.5 trillion dollars in 2023.2 3 Currently, 
a lack of transparency due to contract and 
pricing agreements between purchasers and 
manufacturers of drugs limits insight into net 
drug prices because price comparisons are 
based on retail prices. Net drug prices are the 
prices actually paid by the purchasing health-
care institute, while retail prices exclude 
various individual pricing agreements such 
as rebates.4 The effects of various policy 
measures are, therefore, unavailable to most 
purchasers and policymakers, which makes 
the drug price market opaque and actual 
comparisons of prices impossible.5–8 The 
global drug price discussion is tremendous, 
but it remains unclear how drug prices are 
determined.
By comparing drug prices within and 
across different countries, determinants of 
drug prices can be identified. We make a 
strengths and limitations of this study
 ► A systematic review on drug price comparison 
studies in peer- reviewed literature was conducted 
to assess all recently identified modifiable and non- 
modifiable determinants of drug prices.
 ► Only one published study conducted determinant 
analyses with net drug prices, while the rest includ-
ed retail drug prices.
 ► The structured best- evidence synthesis is able to 
quantify heterogeneous evidence and summarises 
the association between drug price (variance) and 
the reported determinants.
 ► This study design only allows for correlative analysis 
and cannot establish direct causal associations be-
tween determinants and price (variance).
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distinction between determinants that are modifiable by 
policymakers and determinants that are not. Modifiable 
determinants could act as a target for potential interven-
tions to decrease drug costs. Present drug policies are 
highly heterogeneous and have varying effects on drug 
prices. Therefore, identifying and harmonising effective 
price management strategies may aid in accomplishing 
lower prices. However, international and national price 
comparison studies of net drug prices are scarce in the 
literature, which forms a bottleneck to compare drug 
prices. To our knowledge, the first publication that quan-
tified drug price differences was performed in 1971 in the 
USA.9 In this study, the net price paid by the US govern-
ment was compared with the purchasing price of commu-
nity pharmacies for the 50 most prescribed medications. 
Central governmental purchasing by the USA resulted 
in a relative discount of nearly 50% over local pharma-
cies. Since then, research on drug prices (excluding price 
ratios) and, more specifically, net drug prices has been very 
limited, but in recent years some determinants of retail 
drug prices were identified.5 10–13 Most reported deter-
minants are non- modifiable (eg, geographical factors, 
GDP and product age). However, some are modifiable. 
In individual studies, systems allowing for mark- ups (eg, 
processing costs or profit passed on to purchaser), degree 
of market competitiveness, the generics market propor-
tion and degree of governmental intervention (refer-
ence pricing and education about efficacy of generics) 
have been found to influence drug prices in some coun-
tries.14–19 A systematic analysis of modifiable drug price 
determinants that are published in drug price compar-
ison studies is, however, missing.
Therefore, in this systematic review, we aim to identify 
determinants of drug prices and more specifically modi-
fiable determinants that may serve as potential targets for 
drug price optimisation. In addition, we give an overview 
of the recent literature in drug price comparisons and 
execute a best- evidence synthesis of all reported determi-
nants of drug prices.
MethODs
This systematic review was guided by the Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
(PRISMA) statement.20
Patient and public involvement
There were no patients involved in this study.
search strategy and information sources
The databases of PubMed, EMBASE, Web of Science and 
the Cochrane Library were searched until 22 July 2020. We 
aimed to investigate which determinants influence drug 
prices by using comparison studies that measure at least 
one such determinant. All synonyms of the three topics 
of this study, prices, drugs/medicines and benchmark/compar-
ison, were included in the search strategy—with the exclu-
sion of cost- effectiveness—acknowledging the respective 
database formats (eTable 1 of the online supplemental 
materials). All peer- reviewed articles that reported 
drug prices (excluding price ratios) in a benchmark or 
comparative study were included. We did not include 
primary grey literature documents, such as documents of 
non- governmental organisations (NGOs), as our aim was 
to assess academic evidence of modifiable determinants, 
written by independent observers and published in peer- 
reviewed journals. Both national and international studies 
were included, as well as pharmacy or hospital compari-
sons, prospective, transverse and retrospective studies. 
Only articles published between 2004 until and including 
2020 were included for two reasons. First, our aim is to 
investigate current determinants of drug prices. Second, 
articles on this topic published before 2004 were scarce 
and likely less relevant, as the pharmaceutical market 
underwent significant changes in the last 15 years.21 
Articles were excluded if they only reported (a combi-
nation of) policies, efficacy, cost- effectiveness studies or 
studies examining general treatment costs (such as diag-
nosis treatment combinations (DBCs) in the Netherlands). 
We executed a two- way process of reference and citation 
checking of the included articles.
study eligibility and outcomes
The PICO (research format of population, intervention, 
control, outcome) consisted of drug or drug group (P), 
present determinant (I), non- present determinant (C), 
drug price or price variance (O). Therefore, all peer- 
reviewed studies that reported a measure of association 
between drug prices (meaning: not relative prices or 
price indices) or price variance (dependent variable) and 
one or more determinants (independent variable(s)) 
were included.
selection process
First, titles and abstracts (or if unavailable, full text) were 
independently screened by two researchers (JMJD and 
AdA). The full texts of potentially relevant articles were 
independently assessed for inclusion by two researchers 
(JMJD and AdA). Discrepancies between the researchers 
were resolved through discussion and consensus. If no 
consensus was reached, a third researcher (BvdB) was 
consulted.
Data collection and extraction
A standardised extraction worksheet was used to collect 
study characteristics, methods and outcome information 
from all included articles by both AdA and JMJD. The 
extraction worksheet was ultimately cross- checked. The 
following items were collected: first author name, year 
of publication, manuscript title, country of study, study 
design, selection criteria (regarding included medica-
tions, institutes), (type of) price comparison/benchmark, 
studied determinants of drug prices and association 
between determinant and drug price.
risk of bias in individual studies and across studies
Quality assessment of the included studies was done with 
the Quality Assessment Tool for Observational Cohort 
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and Cross- Sectional Studies of the National Institute 
of Health (NIH).22 As the main purpose of this study is 
to give an overview of the field and to conduct a best- 
evidence synthesis, this instrument was only used to assess 
the quality and characteristics of the included studies and 
not to exclude additional studies. This specific assessment 
tool was used because studies were mostly cross- sectional, 
sometimes observational and generally heterogeneous. 
As this tool is only meant to guide researchers in assessing 
such article’s strengths and weaknesses, potential conse-
quences of the identified risk of bias were interpreted 
by three authors (JMJD, AdA, BvdB) and consensus was 
reached based mainly on potential consequences on 
research results, as is also recommended by the NIH. In 
compliance with the assessment tool methods, studies 
were categorised in three quality levels: good (all relevant 
qualifications met), fair (one or two not met) or poor 
(three or more not met).
Within the studies, selective reporting was assessed by 
carefully exploring the entire Results section and supple-
mental material for non- reported associations.
summary measures and evidence synthesis
A qualitative best- evidence synthesis was performed to 
identify determinants of drug prices and variance in drug 
prices. Drug price variance reflects the potentiality of price 
differences of the same drug arising with comparable 
exposure to the analysed determinant. Unfortunately, the 
heterogeneity between studies meant a quantitative anal-
ysis was not feasible. Determinants measured in every study 
were counted. If a determinant was studied three times or 
more, then it was analysed and a best- evidence synthesis 
was conducted. If the determinant was studied once or 
twice, it was only shortly discussed, as the data were consid-
ered to be of insufficient robust quality for qualitative 
analysis. Level of evidence was based on the combination 
of study quality together with the total number of studies 
that measured the determinant. ‘Strong evidence’ for the 
price- modifying effect of a determinant was suggested if 
it was reported by three or more studies with an average 
‘fair quality’ or higher and comparable associations were 
found. ‘Moderate evidence’ for the modifying effect on 
price or price variance of a determinant was suggested 
if it was reported by two ‘fair quality’ studies on average 
or higher than reported comparable associations. Pooled 
results with fewer studies, miscellaneous results or studies 
of poorer quality were considered ‘poor’ or ‘conflicting’, 
depending on these factors.
results
study selection
After duplication removal and title- abstract screening, 85 
full- text articles were screened for eligibility. After full- 
text screening, 31 of these 85 articles were included in 
this systematic review. The reason for exclusion was often 
an irrelevant study outcome, such as drug efficacy, afford-
ability or study design, such as reviews discussing policy. 
A detailed process outline is visualised in eFigure 1 of the 
Supplemental Materials.
Quality assessment
Ten articles of good quality, 16 articles of fair quality and 
5 articles of poor quality were identified. The criteria that 
caused the most differentiation in article quality were 
adjustment for confounding factors, sample size justifi-
cation/power description/variance and effect estimates. 
Table 1 presents a summary of the risk of bias assessment.
study characteristics
Of the 31 included studies, most had a cross- sectional 
design. Seven studies measured drug prices over a period 
of 1–17 years, most often with more than one follow- up. 
Twenty- five studies compared international prices (from 
here: prices) between countries, most often in high- 
income continents or countries such as Europe and/or 
the USA. Only the study by Van Harten et al reported net 
drug prices.5 Twenty- one studies reported retail prices 
(of which three government prices, two wholesale retail 
prices and one out- of- pocket prices) and nine studies 
reported ex- factory prices (table 1). Therefore, unless 
otherwise specified, drug prices indicate retail prices. 
Table 1 displays study characteristics.
Determinants
Table 1 describes all determinants measured per study 
and categorises the scope of the study in international 
versus national context. Table 2 depicts the best- evidence 
synthesis to which this section refers. eTable 2 of the 
online supplemental file 1 shows all determinants that 
were measured less than three times and were therefore 
not included in the best evidence synthesis. Below, the 
most common determinants of drug prices and drug 
price variance are described in further detail.
National wealth
Thirteen studies associated drug prices with national 
wealth, which was measured as a country’s GDP or gross 
national income (GNI) per capita. Determinants in Euro-
pean countries were often studied because of comparable 
national wealth but fairly different drug pricing policies, 
allowing for more accurate evaluation of pricing policy 
efficacy. Three studies compared the most affluent Euro-
pean regions to other European countries, of which one 
included net drug prices. Seven studies compared the USA 
to other high- income countries. Six studies compared 
prices within a country, once in Austria, India, Kenya and 
three times in the USA. These studies addressed differ-
ences between hospitals, pharmacies, subregions and 
states, respectively.
While in various countries drugs became cheaper 
or prices remained stable over time, prices tended to 
increase in the USA compared with other Western coun-
tries, in some instances up to 10% per year.23–25
Medication in Northern Europe was often more expen-
sive compared with southern Europe, although this 
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finding was inconsistent across studies and there was 
no consistent association between cancer drug prices 
and GDP in high- income European countries.5 26–28 
Conversely, after adjustment for PPP (purchasing power 
parity), higher GDP was associated with lower prices.26–28
Across a broad spectrum in high- income countries as 
well as high- income versus middle- income countries, an 
association between GDP and drug prices could not be 
established.5 11 Between middle- income and low- income 
countries, a moderately positive association between 
GDP and prices was found. After PPP adjustment, there 
was a direct relationship between GDP category and the 
frequency of lowest prices: across high, middle and low- 
income countries, high- income countries most often 
had the lowest prices.29 30 PPP- adjusted prices were espe-
cially high in Africa when compared with low- income 
and middle- income countries.31 32 No clear association 
between drug prices and GDP could be established across 
low- income countries.
Market and drugs
Various studies assessed market influence in the form of a 
high proportion of generics or originators (nine studies) 
or patent expiry (three studies). Price- technical constructs 
such as discounts and mark- ups were common in five 
studies, of which the study by Van Harten et al included 
net drug prices and four described retail prices.5 Drug 
studies often focused on anticancer drugs (nine studies) 
or drugs for very specific patient groups such as hepatitis 
C, Alzheimer’s disease or drugs for ophthalmic use. Occa-
sionally, drugs were a random (representative) sample of 
widely used drugs, such as statins, analgesics and broad- 
spectrum antibiotics, most often including generics and 
originator drugs.
High market proportions of originator drugs led to 
high prices as well as price variance in all countries. In 
low- middle and low- middle income countries, price vari-
ance is already significant.33 In addition, a large origi-
nator price variance arises over time in the absence of 
price regulation. This association is not observed for 
generic substitutes. Drug prices in systems allowing for 
mark- ups tend to be higher than systems without. Strong 
evidence for price reduction was found in countries with 
a high generics proportion in the pharmaceutical market. 
Patent expiry was always accompanied by price reduction. 
Conflicting evidence suggests that a more independent 
status of pharmacies (compared with a chain) is associ-
ated with lower drug prices.34 35
Policies and government
Various studies assessed the association of drug prices 
with specific policy measures (three studies for tendering, 
three for regulation scheme/indexation, three for 
central purchasing including one study reporting net 
drug prices). Of all price regulating policy measures, 
the strongest evidence exists for tendering.27 36 37 Pricing 
regulation schemes and indexation schemes reduce price 
and price variance compared with unregulated market 
pricing.23 24 37 Central purchasing by governmental agen-
cies seems to lead to lower prices compared with semi-
public or private purchasing. This effect, however, does 
not hold for net cancer drug prices across European 
countries with the exception of France.5 36 37
DIsCussIOn
This study was conducted to systematically review drug 
price comparison studies about the modifiable determi-
nants of drug prices.
Main findings
We found that literature on net drug prices is very scarce 
and that there is very limited insight in drug pricing 
mechanisms, which makes it impossible for purchasers 
and policymakers to transparently compare drug prices. 
These findings are indicative of an opaque price market. 
As the literature only delivers anecdotal evidence for 
differences in net drug prices, this study is unable to 
comment on determinants of net drug prices to accom-
plish insight in pricing mechanisms which can fuel the 
global drug price discussion.5
Retail prices in an international and national context 
display a high degree of variance and not all variance can 
be explained by the measured determinants in this study. 
Despite this, we found that modifiable determinants that 
were associated with lower prices are as follows: a higher 
generics market portion, discounts, tendering policies, 
central (governmental) purchasing and pricing regula-
tion schemes. Modifiable determinants that were associ-
ated with higher prices are markets with higher originators 
market portion and systems in which mark- ups were 
common. In addition, the highest and most persistently 
increasing prices were seen in the USA, even compared 
with other high- income countries. A higher GDP was 
associated with higher prices in middle- income versus 
low- income countries, but not in high- income versus 
middle- income countries. After PPP adjustment, highest 
relative prices were consistently reported in low- income 
countries.
turning modifiable determinants into policies
The drug market has been subject to dramatic inflation 
in size as well as price over the last decades, in which 
expensive drugs such as anticancer drugs stand out.38 For 
policymakers of national governments, it is of paramount 
importance to know which alterations to the market and 
which government policies lead to lower, more affordable 
drug prices. Our findings about generics and originator 
market portions indicate that increasing the supply of 
generics is associated with price reductions, but this is 
often not the case as a stand- alone measure. For example, 
high- income countries with a relatively open market 
entry consistently experience higher initial prices for 
generics compared with countries with a more regulated 
generics market, such as Scandinavian countries with 
mandatory generic substitution.36 In these countries, 
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prices are half those in the Netherlands and Germany, 
which have a relatively open market.39 Therefore, addi-
tional pricing regulation schemes might be necessary to 
actually achieve such a shift, and our results show various 
effective schemes. Direct price control by regulation on 
expensive drugs such as anticancer drugs likely has more 
influence than percentage discounts. For example, index-
ation to average inflation of these drugs in the UK led to 
an annual inflation of only a quarter percent, compared 
with almost 9% in the unregulated market of the USA 
over a period of approximately 10 years.24 In any case, 
pricing policy in a predominantly originator market is less 
likely to lead to significant price reductions than generics- 
promoting policy.40 41
Tendering led to lower prices and more specifically, 
lower generic- originator differences in various European 
countries. The risks of tendering include a (too) narrow 
focus on price and not quality. This may be of even higher 
importance in countries with limited quality control 
than in Europe and the USA, where market approval is 
granted after a diligent selection process by the European 
Medicines Agency and Food and Drug Administration.36 
In addition, attention to tender frequency is important 
because prolonged supply exclusivity might outmarket 
other suppliers, leading to worsening oligopoly or even 
monopoly. Conversely, because of this exact reason, too 
high tender frequency reduces competitive pressure.42 
Tiered pricing agreements have been successful in 
reducing drugs prices in developing countries multifold 
and are relatively easy to implement, although, within the 
scope of our study, we have not been able to collect addi-
tional proof of this.28 All in all, no intervention should 
be evaluated on its own; new interventions need to be 
weighted in the total ecosystem of interventions. Each 
intervention has different consequences based on the 
timing and sequence of implementation. Moreover, many 
interdependencies exist between existing measures and 
new interventions.43 One intervention is likely to have 
different outcomes in different healthcare systems. An 
earlier extensive review on determinants of pharmaceu-
tical expenditure has also shed light on these dynamic 
properties of market interventions and governmental 
regulation on drug prices (as well as on investments in 
research and development).44
Therefore, we recommend future policy effectivity 
studies to include a careful assessment of (external) 
validity of their results; an extensive description of the 
healthcare system, governmental regularisation and 
market properties.
regional and country-specific differences
Due to the lack of significant price differences between 
middle- income and high- income countries, prices did 
not linearly increase with GDP throughout the entire 
GDP spectrum. In addition, the association of GDP and 
drug prices reversed after PPP adjustment.
On average, a 33% increase in price was found for 
every 50% increase in (unadjusted) wealth per capita 
for a representative set of the WHO essential drugs.15 
This observation is supported by the upsurge of phar-
maceutical expenditure observed in steadily developing 
low- income and middle- income countries.45 Large price 
variance is noted by studies in low- income countries. This 
variance is largely explained by the relatively unorgan-
ised market and lack of pricing regulation. In contrast, 
developed countries generally have more organised price 
referencing systems and direct agreements with pharma-
ceutical companies, which means more expensive drugs 
can be purchased in large- scale volumes.46 Although 
innovative drugs in low- income countries are gradually 
becoming more accessible, the introduction of expensive 
originator alternatives of essential drugs will likely result 
in limited health gain but significantly increased cost.47
A large portion of the observed price differences 
between high- income countries originates from the USA, 
likely because of the unregulated free- market approach. 
For example, the initial price listing of expensive (cancer) 
drugs in the UK is negotiated by the government, in 
contrast to the relatively open market entry in the USA, 
leading to 42% lower prices in the UK.24 Currently, coun-
tries in Europe have a tendency to dovetail their health-
care system design, leading to lower and more normalised 
price distributions across the continent, mostly due to 
external price referencing.21 Indeed, consistent with our 
findings, this leads to further divergence from the USA.48
limitations
The findings are to be interpreted with caution because 
it is likely that large heterogeneity and the lack of net 
pricing data added significantly to the weighting in this 
best- evidence analyses and the outcomes of the synthesis. 
Nonetheless, a significant number of studies reported no 
association between the measured determinant(s) and 
drug price(s), indicating that not only positive findings 
were published.
The lack of net pricing is likely partly due to the fact that 
we excluded primary grey literature documents from our 
main research corpus. Various institutions, most promi-
nently the WHO, are increasing their efforts in assessing 
pharmaceutical expenditure and its determinants as 
shown by a recent overview of grey literature.49 Research 
institutes have set- up various inspiring collaborations with 
governmental and NGO using national databanks (such 
as Austria’s Pharma Price Information, or PPI) or WHO 
data, which are rich and often available at request.32 50 51 
In addition, WHO now promotes and collects various 
drug price databases and occasionally publishes in peer- 
reviewed journals.32 52 Ideally, these studies give rise to 
further collaboration and NGO- supervised observational 
studies in developing countries, allowing academics to 
assess effectiveness of interventions on net drug prices.
We recognise that the included studies only establish 
associations. For identifying causal associations, controlled 
trials are needed which are very hard to execute due to 
a lack of transparency and collaborative effort, as well as 
the difficulty of conducting an intervention ceteris paribus. 
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Many studies reported large measures of uncertainty due 
to non- disclosure of data such as discounts, net prices 
paid, volumes sold, negotiations and arrangements with 
pharmaceutical companies. Therefore, many studies did 
not report an exact representation of the pharmaceutical 
market. Net prices may have been more economical than 
the retail prices reported in the literature on which this 
review is based, but current literature is insufficient to 
give further insight in net drug price determinants. This 
exacerbates the challenge of reducing healthcare costs, 
as real price comparisons are can never be made in this 
state of affairs.
In addition, selection bias (medication selection) is 
likely significant as the most complete or readily available 
data are used, instead of drug price data that might be 
less available, such as price data on confidential pricing 
agreements. On the contrary, the total set of included 
studies comprises a large variety of drugs and countries, 
increasing external validity of these findings.
Further research
The lack of transparency and the high prevalence of non- 
disclosure agreements are likely two of the major drivers 
for drug price differences. We call for an elimination of 
non- disclosure agreements to better understand under-
lying drug price determinants and mechanisms. In addi-
tion, we identified a gap in the representation of national 
studies, as only six national (within- country) analyses were 
identified. Therefore, we were unable to solidly identify 
determinants of price in the national setting.
Additional transparent, open- access research into price 
variance using net drug prices is needed to identify deter-
minants of national and international price variance, 
which can be helpful to governments and regional insti-
tutes such as hospitals alike to improve their purchasing 
strategy and methods. Uniform introduction of pricing 
regulation and publication of net drug prices may ulti-
mately lead to more price transparency and a more 
balanced playing field of countries with a significant 
budget constrain. Such a situation allows for fair negotia-
tions and, ultimately, a more sustainable and transparent 
healthcare sector.
COnClusIOn
Peer- reviewed literature on the determinants of net drug 
paid prices and corresponding pricing mechanisms is 
very scarce. This is remarkable given the rising healthcare 
costs and in particular rising pharmaceutical costs, as well 
the growing societal discussion on mitigating healthcare 
expenditure. Retail drug prices display a high degree of 
variance, both within and between countries. This system-
atic review revealed empirical evidence of determinants 
retailing to a country’s income level, its pharmaceutical 
market system and its policies and government. Policy-
makers may be particularly interested in the policy- related 
determinants of lower retail prices. Drug prices in low- 
income countries are consistently higher after adjustment 
for PPP, indicating that lower- income countries still pay 
the highest relative retail prices. Various easily imple-
mentable governmental interventions and regulations, as 
well as modifiable market system- related characteristics, 
are consistently associated with lower retail prices and 
thus potential price reduction, such as increasing the 
generic portions of the drug market, governmental poli-
cies such as tendering, central purchasing and regulation 
schemes targeting annual price inflation, patent regula-
tion and mark- ups, which might aid developing countries 
in closing the gap of purchasing power- adjusted prices 
with high- income countries in the future. Most prom-
inently, national and international net price studies are 
necessary to quantify the effectiveness of these policy 
measures on net drug prices. We call for openness of net 
drug price data, as this is our key to change the health-
care cost burden.
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eTable 1: PubMed Search Strategy 3 
((((((("Pharmaceutical Preparations"[Mesh]) OR ((medicine[Title/Abstract] OR 4 
medicines[Title/Abstract] OR drug[Title/Abstract] OR drugs[Title/Abstract] OR 5 
pharmaceutical[Title/Abstract] OR pharmaceuticals[Title/Abstract] OR medication[Title/Abstract] OR 6 
medications[Title/Abstract])))) AND ((price[Title/Abstract] OR prices[Title/Abstract] OR 7 
pricing[Title/Abstract])))) AND (("Benchmarking"[Mesh]) OR ((benchmark[Title/Abstract] OR 8 
compare[Title/Abstract] OR comparison[Title/Abstract] OR comparisons[Title/Abstract]))))) NOT 9 
cost-effectiveness AND (full text[sb]) 10 
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HQ: high quality, FQ: fair quality, LQ: low quality, NS: not significant, + : positive effect, - : negative effect, EPR: external price referencing 26 
 27 
Category Determinant Studies Effect References 
Geography Africa (vs. low-income)  2 HQ  +, +  [31, 32] 
 
France  1 LQ + [5] 
 India 2 FQ -,- [39, 56] 
(Pharmaceutical) market Number of manufacturers 1 LQ NS [62] 
 
Tiered pricing agreement 1 HQ - [28] 
 
Independency of pharmacy 2 FQ -, NS [34, 35] 
 Recession 1 HQ - [26] 
Policy Governmental health plan 1 FQ - [61] 
 
EPR 1 LQ, 1 FQ -, - [23, 36] 
 
Transparency 1 FQ  - [53] 
 
Free market 1 LQ + [39] 
 
Generics tax 1 HQ + [32] 
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